A prospective randomized trial of lafutidine vs rabeprazole on post-ESD gastric ulcers

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

553

HTML

3672

Figures (1-1)

414

Tables (1-4)

198

Sum=4837

Jan 16, 2010 (publication date) through Jul 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Endoscopy

ISSN

1948-5190

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastrointest Endosc. Jan 16, 2010; 2(1): 36-40
Published online Jan 16, 2010. doi: 10.4253/wjge.v2.i1.36

Table 2 Characteristics of patients and lesions

	Lafutidine	Rabeprazole	P
Gender (M:F)	21:8	23:8	0.607
Age (mean ± SD)	65.3 ± 8.0	65.4 ± 9.0	0.769
Body mass index (kg/m²) (mean ± SD)	23.2 ± 3.1	23.0 ± 2.7	0.751
Anti-H. pylori antibody (positive:negative)	23:6	24:7	0.729
Ulcerated lesion (yes:no)	5:25	1:33	0.181
Location (upper:middle:lower)	1:16:13	4:20:10	0.251
Lesion depth (mucosal layer: submucosal layer)	27:3	33:1	0.677
Ulcer size immediately after ESD (mm) (mean ± SD)	33.3 ± 9.2	34.7 ± 11.3	0.635

Patient characteristics were analyzed on patient number basis, whereas lesion or ulcer characteristics were analyzed on tumor/ulcer number basis.

Citation: Ohya TR, Endo H, Kawagoe K, Yanagawa T, Hanawa K, Ohata K, Asayama M, Hisatomi K, Teratani T, Gunji T, Sato H, Matsuhashi N. A prospective randomized trial of lafutidine vs rabeprazole on post-ESD gastric ulcers. World J Gastrointest Endosc 2010; 2(1): 36-40
URL: https://www.wjgnet.com/1948-5190/full/v2/i1/36.htm
DOI: https://dx.doi.org/10.4253/wjge.v2.i1.36